Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

8.540 -0.530 (-5.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile. 
Via Benzinga
Signet Jewelers, BGM Group, StoneCo, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Semtech Posts Better-Than-Expected Earnings, Joins Rubrik, DocuSign, PagerDuty And Other Big Stocks Moving Higher On Friday
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts
Via Benzinga
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Earnings Scheduled For May 12, 2025
Via Benzinga
What to Expect from Regenxbio's Earnings
Via Benzinga
The One-Minute Market Report - Saturday, April 26
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, ETFs, and stocks that moved the market higher, as well as the market segments that defied the... 
Via Talk Markets
Topics ETFs Stocks / Equities
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
What's going on in today's after hours session
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Where Regenxbio Stands With Analysts
Via Benzinga
5 Analysts Have This To Say About Regenxbio
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts
Via Benzinga
Earnings Scheduled For March 13, 2025
Via Benzinga
Assessing Regenxbio: Insights From 5 Financial Analysts
Via Benzinga
Where Regenxbio Stands With Analysts
Via Benzinga
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and declining appeal in retinal diseases. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Workday, Apollo Global To Join S&P 500 Index In Quarterly Balance
They'll join the index before the open on Dec. 23 as part of a quarterly rebalance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
What's Going On With REGENXBIO Shares Monday?
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy. 
Via Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
Why Is Clearside Biomedical Stock Gaining Today?
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
Via Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.